Loading
Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer.
Robert Coleman (US Oncology Research, Texas) was principal investigator of ARIEL3, which established rucaparib maintenance in recurrent ovarian cancer, and of GOG-0213, which found no survival benefit from secondary cytoreductive surgery but confirmed bevacizumab's benefit at relapse. He served as GOG programme director and has led many NRG gynaecological trials.
Shares PARP inhibitors, VEGF / VEGFR, PARP, Anti-angiogenic therapy and the tags ovarian, parp.
Shares PARP inhibitors, PARP, Ovarian cancer and the tags ovarian, parp.
Shares PARP inhibitors, PARP, Ovarian cancer and the tags ovarian, parp.
Shares Ovarian cancer and the tags ovarian, surgery.
Shares Ovarian cancer and the tags ovarian, surgery.
Shares PARP inhibitors, PARP, Ovarian cancer and the tag parp.
Shares PARP inhibitors, PARP, Ovarian cancer and the tag ovarian.
Shares PARP inhibitors, PARP and the tag parp.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/